Rocket Pharmaceuticals (RCKT) Capital Leases (2020 - 2025)
Historic Capital Leases for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Q3 2025 value amounting to $19.4 million.
- Rocket Pharmaceuticals' Capital Leases fell 3.61% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year decrease of 3.61%. This contributed to the annual value of $19.4 million for FY2024, which is 15.5% up from last year.
- Per Rocket Pharmaceuticals' latest filing, its Capital Leases stood at $19.4 million for Q3 2025, which was down 3.61% from $19.4 million recorded in Q2 2025.
- Rocket Pharmaceuticals' Capital Leases' 5-year high stood at $19.4 million during Q4 2024, with a 5-year trough of $19.0 million in Q1 2021.
- In the last 5 years, Rocket Pharmaceuticals' Capital Leases had a median value of $19.3 million in 2023 and averaged $19.3 million.
- Its Capital Leases has fluctuated over the past 5 years, first skyrocketed by 93.36% in 2021, then decreased by 3.61% in 2025.
- Quarter analysis of 5 years shows Rocket Pharmaceuticals' Capital Leases stood at $19.1 million in 2021, then grew by 0.65% to $19.3 million in 2022, then increased by 0.44% to $19.4 million in 2023, then increased by 0.16% to $19.4 million in 2024, then dropped by 0.04% to $19.4 million in 2025.
- Its last three reported values are $19.4 million in Q3 2025, $19.4 million for Q2 2025, and $19.4 million during Q1 2025.